Oslo, 4 July

Reference is made to the stock exchange announcement by Observe Medical ASA (the
"Company" or "Observe Medical", OSE ticker "OBSVR") on 1 July 2025, regarding
the board of directors' resolution to increase the share capital of the Company
by the issuance of 6,000,000 new shares to Jiangsu Hongxin Medical Technology
Co. Ltd ("Jiangsu") in connection with the private placement, at a subscription
price of NOK 0.50 per share (the "Jiangsu Conversion Shares") through set-off
against a receivable amounting to NOK 3,000,000 that Jiangsu had against the
Company (following transfer of said receivable from Observe Medical AB to the
Company pursuant to a debt transfer agreement dated 27 June 2025).

The share capital increase pertaining to the issuance of the Jiangsu Conversion
Shares has today been registered with the Norwegian Register of Business
Enterprises (Nw. Foretaksregisteret).

The Company's registered share capital is NOK 10,608,533.04, divided into
25,258,412 shares, each with a nominal value of NOK 0.42.

The Jiangsu Conversion Shares will be registered with the Norwegian Central
Securities Depository Euronext Securities Oslo (the "VPS") on a separate ISIN
from the existing shares of the Company, pending approval and publication by the
Company of a prospectus (the "Prospectus") and will thus not be tradable on
Euronext Expand Oslo until the Prospectus has been approved by the Financial
Supervisory Authority of Norway (the "NFSA") and published by the Company, upon
which the Jiangsu Conversion Shares will be transferred to the Company's
ordinary ISIN in the VPS and be admitted to trading on Euronext Expand Oslo. The
Prospectus is expected to be approved by the NFSA and published by the Company
at the end of Q3 2025.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.